ADVM adverum.com Gross Profit Rate

Corporate emblem and logo of Adverum Biotechnologies (ADVM)

Adverum Biotechnologies management aims to develop long-term treatments for ocular pathologies through gene therapy. The innovative Ixo-vec platform, supported by patent protection, could transform the market by replacing regular injections. The asset possesses high macro-resilience and is not subject to seasonality. The gross profit margin on GURU.Markets reflects current dynamics, where the metric value is 0.00.

Adverum (ADVM) Gross Profitability: for the period 07/04/2022 - 12/20/2025

Financial and market metric breakdowns for Adverum Biotechnologies Inc. (ADVM)

- stock value and consensus price forecast:
Fundamental valuation:ADVM - adverum.com
Manufactured products of Adverum Biotechnologies, Inc.

Portfolio managers evaluate the operating model of Adverum Biotechnologies (ADVM) through the share of revenue remaining after deducting direct production costs, which allows for the measurement of fundamental profit generation efficiency. By analyzing gross profit margins, investors can see how patent protection for viral vectors and the complexity of biosynthesis create high added value, confirming the stability of the company's market position within the gene therapy segment.